karmma-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Published 1 year ago • 144 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:40
lba: karmma-3 results - ide-cel vs standard regimens in triple-class exposed multiple myeloma
-
2:18
karmma-3 trial updates: ide-cel versus soc in triple-class exposed r/r multiple myeloma
-
4:04
ide-cel versus standard regimens in tce r/r multiple myeloma: updated analysis of karmma-3
-
3:54
karmma-3: pros in patients with tce r/r myeloma treated with ide-cel vs standard regimens
-
2:16
updates from the karmma-3 trial: safety profile of ide-cel in tce r/r multiple myeloma
-
1:29
final results of karmma-3: ide-cel in r/r mm
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
14:06
interpreting myeloma tests- case studies
-
23:23
identifying and treating high-risk patients in 2023
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
2:06
subanalysis of the karmma trial: predicting complete response to car-t in multiple myeloma
-
5:44
dara-cvrd, v-asct and dara-vrd consolidation in uhir ndmm and ppcl compared with myeloma xi/xi ...
-
4:03
ikema long-term sub-group analysis: isa-kd for 1q21 multiple myeloma
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
0:45
key trials in cll and designing a concept for treatment
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
1:30
real-world treatment patterns in third-line therapy for r/r myeloma
-
1:36
kt-333: a first-in-class stat3 degrader
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
5:15
promising clinical trials for multiple myeloma: karmma, cartitude and evolve